Trypanosoma cruzi calreticulin: A novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity

Immunobiology

Volumn 216, Issue 1-2, 2011, Pages 265-273

  Ramírez, Galia ^a   Valck, Carolina ^a   Molina, María C ^a   Ribeiro, Carolina H ^a   López, Nandy ^a   Sánchez, Gittith ^a   Ferreira, Viviana P ^b   Billetta, Rosario ^a   Aguilar, Lorena ^a   Maldonado, Ismael ^a   Cattán, Pedro ^c   Schwaeble, Wilhelm ^d   Ferreira, Arturo ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c UNIVERSITY OF CHILE   (Chile)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

C1q; Immunoglobulins; Infectivity; Trypanosoma cruzi calreticulin

Indexed keywords

CALRETICULIN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN F(AB) FRAGMENT; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CELL SURFACE; CHAGAS DISEASE; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; CONTROLLED STUDY; FEMALE; HOST CELL; HOST PARASITE INTERACTION; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARASITE VIRULENCE; PARASITEMIA; PRIORITY JOURNAL; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE; VERO CELL;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, PROTOZOAN; CALRETICULIN; CELL LINE; CHAGAS DISEASE; COMPLEMENT C1; IMMUNITY, HUMORAL; IMMUNIZATION; MACROPHAGES; MICE; PARASITEMIA; PROTEIN BINDING; TRYPANOSOMA CRUZI; VIRULENCE;

EID: 78649498983     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.04.001     Document Type: Article

References (47)

1. Aguilar L., Ramirez G., Valck C., Molina M.C., Rojas A., Schwaeble W., Ferreira V., Ferreira A. F(ab')2 antibody fragments against Trypanosoma cruzi calreticulin inhibit its interaction with the first component of human complement. Biol. Res. 2005, 38:187-195.
2. Aguillon J.C., Bustos C., Vallejos P., Hermosilla T., Morello A., Repetto Y., Hellman U., Orn A., Ferreira A. Purification and preliminary sequencing of Tc-45, an immunodominant Trypanosoma cruzi antigen: absence of homology with cruzipain, cruzain, and a 46-kilodalton protein. Am. J. Trop. Med. Hyg. 1995, 53:211-215.
3. Aguillon J.C., Ferreira L., Perez C., Colombo A., Molina M.C., Wallace A., Solari A., Carvallo P., Galindo M., Galanti N., Orn A., Billetta R., Ferreira A. Tc45, a dimorphic Trypanosoma cruzi immunogen with variable chromosomal localization, is calreticulin. Am. J. Trop. Med. Hyg. 2000, 63:306-312.
4. Aguillon J.C., Harris R., Molina M.C., Colombo A., Cortes C., Hermosilla T., Carreno P., Orn A., Ferreira A. Recognition of an immunogenetically selected Trypanosoma cruzi antigen by seropositive chagasic human sera. Acta Trop. 1997, 63:159-166.
5. Aguillon J.C., Hermosilla T., Molina M.C., Morello A., Repetto Y., Orn A., Ferreira A. Trypanosoma cruzi: H2 complex and genetic background influence on the humoral immune response against epimastigotes. Int. J. Parasitol. 2000, 30:981-984.
6. Aguillón J.C., Ramos R., Chiong M., Vallejos P., Ferreira A. Soybean proteins: alternative blocking agents for immunoassays using nitrocellulose or plastic solid phases. Biol. Res. 1992, 25.
7. Aida Y., Pabst M.J. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J. Immunol. Methods 1990, 132:191-195.
8. Araya J.E., Cornejo A., Orrego P.R., Cordero E.M., Cortez M., Olivares H., Neira I., Sagua H., da Silveira J.F., Yoshida N., Gonzalez J. Calcineurin B of the human protozoan parasite Trypanosoma cruzi is involved in cell invasion. Microbes Infect. 2008, 10:892-900.
9. Bisaggio D.F., Campanati L., Pinto R.C., Souto-Padron T. Effect of suramin on trypomastigote forms of Trypanosoma cruzi: changes on cell motility and on the ultrastructure of the flagellum-cell body attachment region. Acta Trop. 2006, 98:162-175.
10. Bohlson S.S., Fraser D.A., Tenner A.J. Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol. Immunol. 2007, 44:33-43.
11. Boscardin S.B., Kinoshita S.S., Fujimura A.E., Rodrigues M.M. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect. Immun. 2003, 71:2744-2757.
12. Burton D.R., Woof J.M. Human antibody effector function. Adv. Immunol. 1992, 51:1-84.
13. Castro J.A., Diaz de Toranzo E.G. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed. Environ. Sci. 1988, 1:19-33.
14. Chagas C. Nova tripanozomiase humana: Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem. Inst. Oswaldo Cruz 1909, 1:159-218.
15. DaRocha W.D., Otsu K., Teixeira S.M., Donelson J.E. Tests of cytoplasmic RNA interference (RNAi) and construction of a tetracycline-inducible T7 promoter system in Trypanosoma cruzi. Mol. Biochem. Parasitol. 2004, 133:175-186.
16. Dias J.C., Silveira A.C., Schofield C.J. The impact of Chagas disease control in Latin America: a review. Mem. Inst. Oswaldo Cruz 2002, 97:603-612.
17. Faundez M., Pino L., Letelier P., Ortiz C., Lopez R., Seguel C., Ferreira J., Pavani M., Morello A., Maya J.D. Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi. Antimicrob. Agents Chemother. 2005, 49:126-130.
18. Ferreira V., Molina M.C., Schwaeble W., Lemus D., Ferreira A. Does Trypanosoma cruzi calreticulin modulate the complement system and angiogenesis?. Trends Parasitol. 2005, 21:169-174.
19. Ferreira V., Valck C., Sanchez G., Gingras A., Tzima S., Molina M.C., Sim R., Schwaeble W., Ferreira A. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J. Immunol. 2004, 172:3042-3050.
20. Galeotti C., Maddur M.S., Kazatchkine M.D., Mouthon L., Kaveri S.V. Mechanisms of action of IVIG in autoimmune and inflammatory disorders: recent developments. Transfus. Clin. Biol. 2009.
21. Garg N., Tarleton R.L. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect. Immun. 2002, 70:5547-5555.
22. Gerloni M., Lo D., Ballou W.R., Zanetti M. Immunological memory after somatic transgene immunization is positively affected by priming with GM-CSF and does not require bone marrow-derived dendritic cells. Eur. J. Immunol. 1998, 28:1832-1838.
23. Gold L.I., Eggleton P., Sweetwyne M.T., Van Duyn L.B., Greives M.R., Naylor S.M., Michalak M., Murphy-Ullrich J.E. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J. 2009.
24. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 1997, 158:4591-4601.
25. Kollien A.H., Schmidt J., Schaub G.A. Modes of association of Trypanosoma cruzi with the intestinal tract of the vector Triatoma infestans. Acta Trop. 1998, 70:127-141.
26. Kroemer G., El-Deiry W.S., Golstein P., Peter M.E., Vaux D., Vandenabeele P., Zhivotovsky B., Blagosklonny M.V., Malorni W., Knight R.A., Piacentini M., Nagata S., Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 2005, 12(Suppl. 2):1463-1467.
27. Mahvi D.M., Sheehy M.J., Yang N.S. DNA cancer vaccines: a gene gun approach. Immunol. Cell Biol. 1997, 75:456-460.
28. Marcelain K., Colombo A., Molina M.C., Ferreira L., Lorca M., Aguillon J.C., Ferreira A. Development of an immunoenzymatic assay for the detection of human antibodies against Trypanosoma cruzi calreticulin, an immunodominant antigen. Acta Trop. 2000, 75:291-300.
29. Mellstedt H., Fagerberg J., Frodin J.E., Henriksson L., Hjelm-Skoog A.L., Liljefors M., Ragnhammar P., Shetye J., Osterborg A. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr. Opin. Hematol. 1999, 6:169-175.
30. Michalak M., Lynch J., Groenendyk J., Guo L., Robert Parker J.M., Opas M. Calreticulin in cardiac development and pathology. Biochim. Biophys. Acta 2002, 1600:32-37.
31. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., Metivier D., Larochette N., van Endert P., Ciccosanti F., Piacentini M., Zitvogel L., Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
32. Painter R.H. The C1q receptor site on human immunoglobulin G. Can. J. Biochem. Cell Biol. 1984, 62:418-425.
33. Pasquini S., Xiang Z., Wang Y., He Z., Deng H., Blaszczyk-Thurin M., Ertl H.C. Cytokines and costimulatory molecules as genetic adjuvants. Immunol. Cell Biol. 1997, 75:397-401.
34. Ribeiro C.H., Lopez N.C., Ramirez G.A., Valck C.E., Molina M.C., Aguilar L., Rodriguez M., Maldonado I., Martinez R., Gonzalez C., Troncoso R., Lavandero S., Gingras A.R., Schwaeble W., Ferreira A. Trypanosoma cruzi calreticulin: a possible role in Chagas' disease autoimmunity. Mol. Immunol. 2009, 46:1092-1099.
35. Rimoldi M.T., Tenner A.J., Bobak D.A., Joiner K.A. Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes. J. Clin. Invest. 1989, 84:1982-1989.
36. Robinson T.M., Nelson R.G., Boyer J.D. Parasitic infection and the polarized Th2 immune response can alter a vaccine-induced immune response. DNA Cell Biol. 2003, 22:421-430.
37. Rodrigues M.M., Ribeirao M., Pereira-Chioccola V., Renia L., Costa F. Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect. Immun. 1999, 67:3855-3863.
38. Sanbrook, J., 1989. Molecular cloning, a laboratory manual. Capítulo 1: plasmids vectors, USA.
39. Steino A., Jorgensen C.S., Laursen I., Houen G. Interaction of C1q with the receptor calreticulin requires a conformational change in C1q. Scand. J. Immunol. 2004, 59:485-495.
40. Valck C., Ramírez G., López N., Ribeiro C., Maldonado I., Sánchez G., Ferreira V., Schwaeble W., Ferreira A. Molecular mechanisms involved in the inactivation of the first component of human complement by Trypanosoma cruzi calreticulin. Mol. Immunol. 2010, 47:1516-1521.
41. Vani J., Elluru S., Negi V.S., Lacroix-Desmazes S., Kazatchkine M.D., Bayary J., Kaveri S.V. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun. Rev. 2008, 7:440-444.
42. Wanderley J.L., Moreira M.E., Benjamin A., Bonomo A.C., Barcinski M.A. Mimicry of apoptotic cells by exposing phosphatidylserine participates in the establishment of amastigotes of Leishmania (L) amazonensis in mammalian hosts. J. Immunol. 2006, 176:1834-1839.
43. Warren T.L., Weiner G.J. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr. Opin. Hematol. 2000, 7:168-173.
44. WHO Control of Chagas disease. World Health Org. Tech. Rep. Ser. 2002, 905(i-vi):1-109. back cover.
45. Xu Y., Oomen R., Klein M.H. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement. J. Biol. Chem. 1994, 269:3469-3474.
46. Yoshida N. Molecular basis of mammalian cell invasion by Trypanosoma cruzi. Ann. Acad. Bras. Cienc 2006, 78:87-111.
47. Yoshida N., Cortez M. Trypanosoma cruzi: parasite and host cell signaling during the invasion process. Subcell. Biochem. 2008, 47:82-91.